Efficacy of ustekinumab for ulcerative colitis through 2 years: Results of the UNIFI maintenance study and long-term extension

被引：0
|
作者：
Panaccione, R. [1 ]
Sandborn, W. J. [2 ]
Sands, B. E. [3 ]
Marano, C. [4 ]
O'Brien, C. D. [4 ]
Zhang, H. [5 ]
Johanns, J. [5 ]
Zhou, Y. [5 ]
Peyrin-Biroulet, L. [6 ]
Hisamatsu, T. [7 ]
Danese, S. [8 ]
机构：
[1] Univ Calgary, Ctr Inflammatory Bowel Dis, Calgary, AB, Canada
[2] Univ Calif San Diego, Gastroenterol, La Jolla, CA 92093 USA
[3] Icahn Sch Med Mt Sinai, Gastroenterol, New York, NY 10029 USA
[4] Janssen Res & Dev LLC, Immunol, Spring House, PA USA
[5] Janssen Res & Dev LLC, Clin Biostats, Spring House, PA USA
[6] Nancy Univ Hosp, Gastroenterol, Nancy, France
[7] Kyorin Univ, Internal Med, Tokyo, Japan
[8] Humanitas Res Hosp, Gastroenterol, Milan, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP12
引用
收藏
页码：S049 / S049
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetics and Immunogenicity of Maintenance Therapy With Ustekinumab: 2-Year Results From the UNIFI Long-Term Extension Study
    Adedokun, Omoniyi
    Panaccione, Remo
    Hisamatsu, Tadakazu
    Abreu, Maria T.
    Leong, Rupert W. L.
    Rowbotham, David
    Marano, Colleen
    Zhou, Yiying
    Zhang, Hongyan
    Danese, Silvio
    Afif, Waqqas
    Peyrin-Biroulet, Laurent
    Sandborn, William J.
    Sands, Bruce E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S437 - S437
  • [22] Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extension
    Danese, S.
    Panaccione, R.
    Peyrin-Biroulet, L.
    Marano, C.
    O'Brien, C. D.
    Zhang, H.
    Zhou, Y.
    Johanns, J.
    Scherl, E.
    Leong, R. W. L.
    Rowbotham, D. S.
    Arasaradnam, R. P.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S403 - S403
  • [23] EFFICACY AND SAFETY OF USTEKINUMAB AS MAINTENANCE THERAPY IN ULCERATIVE COLITIS: WEEK 44 RESULTS FROM UNIFI
    Sands, Bruce E.
    Sandborn, William J.
    Panaccione, Remo
    O'Brien, Christopher D.
    Zhang, Hongyan
    Johanns, Jewel
    Peyrin-Biroulet, Laurent
    Van Assche, Gert A.
    Danese, Silvio
    Targan, Stephan R.
    Abreu, Maria T.
    Hisamatsu, Tadakazu
    Szapary, Philippe
    Marano, Colleen W.
    GASTROENTEROLOGY, 2019, 156 (06) : S181 - S181
  • [24] Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI
    Sandborn, W. J.
    Sands, B. E.
    Panaccione, R.
    O'Brien, C. D.
    Zhang, H.
    Johanns, J.
    Peyrin-Biroulet, L.
    Van Assche, G.
    Danese, S.
    Targan, S. R.
    Abreu, M. T.
    Hisamatsu, T.
    Szapary, P.
    Marano, C.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S26 - S26
  • [25] Dose adjustment in patients with moderate to severe ulcerative colitis: results from year 3 of the UNIFI maintenance study long-term extension
    Rowbotham, D. S.
    Scherl, E. J.
    Sands, B. E.
    Panaccione, R.
    Peyrin-Biroulet, L.
    Zhang, H.
    Miao, Y.
    Leong, R. W.
    Afif, W.
    Arasaradnam, R. P.
    Danese, S.
    Marano, C.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S488 - S489
  • [26] Efficacy and Safety of Ustekinumab (UST) as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFI
    Marone, Colleen
    Sandborn, William J.
    Sands, Bruce E.
    Panaccione, Remo
    O'Brien, Christopher D.
    Zhang, Hongyan
    Johanns, Jewel
    Peyrin-Biroulet, Laurent
    van Assche, Gert
    Danese, Silvio
    Targan, Stephan
    Abreu, Maria T.
    Hisamatsu, Tadakazu
    Szapary, Philippe
    SWISS MEDICAL WEEKLY, 2019, : 27S - 27S
  • [27] Effect of Ustekinumab Maintenance Therapy on Stool Frequency and Rectal Bleeding Through 2 Years in the UNIFI Phase 3 Study in Ulcerative Colitis
    Abreu, Maria T.
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    Marano, Colleen
    Zhou, Yiying
    Zhang, Hongyan
    Leong, Rupert W. L.
    Rowbotham, David
    Panaccione, Remo
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S398 - S398
  • [28] Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy
    Panaccione, Remo
    Danese, Silvio
    Sandborn, William J.
    O'Brien, Christopher D.
    Zhou, Yiying
    Zhang, Hongyan
    Adedokun, Omoniyi J.
    Tikhonov, Ilia
    Targan, Stephan
    Abreu, Maria T.
    Hisamatsu, Tadakazu
    Scherl, Ellen J.
    Leong, Rupert W.
    Rowbotham, David S.
    Arasaradnam, Ramesh P.
    Sands, Bruce E.
    Marano, Colleen
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (11-12) : 1658 - 1675
  • [29] Long term efficacy and safety of Ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 years
    Sandborn, W.
    Rutgeerts, P.
    Gasink, C.
    Jacobstein, D.
    Gao, L. -L.
    Johanns, J.
    Sands, B.
    Hanauer, S. B.
    Targan, S.
    Ghosh, S.
    de Villiers, W. J. S.
    Colombel, J. -F.
    Feagan, B. G.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S6 - S6
  • [30] LONG TERM EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH 2 YEARS
    Sandborn, W. J.
    Rutgeerts, P.
    Gasink, C.
    Jacobstein, D.
    Gao, L.
    Johanns, J.
    Sands, B.
    Hanauer, S.
    Targan, S.
    Ghosh, S.
    de Villiers, W. J. S.
    Colombel, J. F.
    Feagan, B. G.
    GUT, 2017, 66 : A22 - A22
12345